#SFHS2611619AFrance Adds FUBELV to Reimbursable Medicines List
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
This order adds FUBELV to France’s list of medicines reimbursed by social health insurance for specific inflammatory diseases, including rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, juvenile idiopathic arthritis, and plaque psoriasis. Patients may now receive insurance coverage for FUBELV only when it is used for the listed conditions and clinical situations, such as inadequate response or intolerance to standard treatments. Healthcare providers, pharmacies, insurers, and hospitals will need to apply the reimbursement limits exactly as defined.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Adds FUBELV to the list of medicines reimbursed by French social health insurance.
- Limits reimbursement to specified inflammatory diseases and defined treatment conditions.
- Covers certain adult, child, and adolescent uses where standard treatments have failed, are not tolerated, or are unsuitable.
Obligations
What this law requires
Only provide social health insurance reimbursement or coverage for FUBELV when it is prescribed for one of the therapeutic indications expressly listed in the order.
For adult patients with moderately to severely active rheumatoid arthritis, reimburse or cover FUBELV only where there has been an inadequate response to disease-modifying antirheumatic drugs, including methotrexate, unless methotrexate is contraindicated.
For rheumatoid arthritis, reimburse or cover FUBELV monotherapy only where the patient is intolerant to methotrexate or continued methotrexate treatment is unsuitable.
For adult patients with active and progressive psoriatic arthritis, reimburse or cover FUBELV only where there has been an inadequate response to prior disease-modifying treatment.
For adult patients with severe active ankylosing spondylitis, reimburse or cover FUBELV only where there has been an inadequate response to conventional treatment.